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Gastrointestinal motility is inﬂuenced by adrenergic modulation. Our aim was to identify speciﬁc subtypes
of adrenergic receptors involved in inhibitory mechanisms that modulate gut smooth muscle contractile
activity.Muscle strips of rat ileal longitudinalmusclewere evaluated for spontaneous contractile activity and
for equimolar dose-responses (107 to 3 × 105 M) to the adrenergic agents norepinephrine (nonselective
agonist), phenylephrine (α1-agonist), clonidine (α2-agonist), prenalterol (β1-agonist), ritodrine (β2-
agonist), andZD7114 (β3-agonist) in the presence and absence of tetrodotoxin (nonselective nerve blocker).
Norepinephrine (3 × 105 M) inhibited 65  6% (mean  SEM) of spontaneous contractile activity.
The same molar dose of ritodrine, phenylephrine, or ZD7114 resulted in less inhibition (46  7%,
31  5%, and 39  3%, respectively; P  0.05). The calculated molar concentration of ZD7114 needed
to induce 50% inhibition was similar to that of norepinephrine, whereas higher concentrations of
phenylephrine or ritodrine were required. Clonidine and prenalterol had no effect on contractile activity.
Blockade of intramural neural transmission by tetrodotoxin affected the responses to ritodrine and
phenylephrine (but not to norepinephrine or ZD7114), suggesting that these agents exert part of their
effects via neurally mediated enteric pathways. Our results suggest that adrenergic modulation of
contractile activity in the rat ileum ismediated primarily bymuscular β3-, β2-, andα1-receptormechanisms;
the latter two also involve neural pathways. (J GASTROINTEST SURG 2005;9:227–235)  2005 The Society
for Surgery of the Alimentary Tract
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receptors, β-adrenergic receptorsCoordination and modulation of gastrointestinal
motor activity are dependent on the interaction of two
complex neural inputs: the enteric nervous system,
which is completely intrinsic within the bowel wall,
and the central nervous system, sending its inﬂuences
through the extrinsic nerves to the gut (vagal, sympa-
thetic).1 Interactions between the central nervous
system and the enteric nervous system are important
in gastrointestinal responses to stress, eating, and
behavior.2
Vagal motor pathways modulate mainly the upper
gastrointestinal tract and the distal colon and rectum. 2005 The Society for Surgery of the Alimentary Tract
Published by Elsevier Inc.In the small bowel, vagal inputs are supplied to myen-
teric neurons.3 These enteric neurons inﬂuence the
generation of motor patterns.
The intestinal sympathetic nervous system consists
of nerve cell bodies located in the prevertebral ganglia
with their postganglionic ﬁbers entering the gut. No
adrenergic nerve cell bodies are present in the gut
wall.1 Most, if not all, sympathetic postganglionic
ﬁbers affecting motility are thought to synapse in the
enteric nervous system and not directly on smooth
muscle cells. Indeed, adrenergic nerves do not syn-
apse directly on nonsphincter muscle cells in the gut.4Presented in part at the Forty-Third Annual Meeting of The Society for Surgery of the Alimentary Tract, San Francisco, California, May
19–22, 2002 (poster presentation).
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the enteric nervous system, we found strong, adrener-
gically mediated inhibitory motor mechanisms in rat
jejunum and ileum occurring preferentially at the
level of these smooth muscle cells rather than in
the enteric nervous system5,6; these effects appeared
to be independent of input from the enteric ner-
vous system.
Therefore, one approach to target gastrointes-
tinal motility disorders through adrenergic pathways
would be to direct the pharmacologic therapy at the
receptors occurring in the gut on smoothmuscle cells.
To date, therapeutic approaches targeting adrenergic
pathways in the gastrointestinal tract have not been
very successful, in part because of substantial cardio-
vascular side effects of the agents used.7
Therefore, mechanisms involved in modulating
contractile activity of the gut mediated by speciﬁc
subtypes of adrenergic receptors are of considerable
interest. Our ﬁrst aim was to identify which adrener-
gic receptor subtypes mediate inhibition of spon-
taneous contractile activity. Second, we wanted to
determine if these receptor-speciﬁc mechanisms were
mediated at the level of the smooth muscle and/or
via the enteric nervous system. Our hypothesis was
that both α1- and β2-receptor mechanisms mediate
the inhibitory responses and that these mechanisms
are active directly at the level of the smoothmuscle and
not indirectly via effects mediated through the enteric
nervous system.
METHODS
Preparation of Tissue
Procedures and animal care were performed ac-
cording to the guidelines of the Department of Agri-
culture of the Canton of Bern, Switzerland. Male
Wistar rats were used in all experiments. Anesthesia
was achieved with intraperitoneal sodiumpentobarbi-
tal (5mg/100 g; Abbott Laboratories,North Chicago,
IL). A 5-cm segment of the ileum was removed begin-
ning 2 cmorad to the ileocecal valve and stored in cold
Krebs-Ringer buffer (concentration in mM: NaCl
118.3, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2,
NaHCO3 25.0, calcium disodium edetate 0.26, and
glucose 11.1). The distal end of the specimen was
marked.
Recording of Contractile Activity
The segment of the distal ileum was immersed in
chilled, modiﬁed Krebs-Ringer bicarbonate solu-
tion and opened along the mesenteric border. The
tissue was pinned ﬂat in a Petri dish, and eight
full-thickness muscle strips per rat were prepared inthe direction of the longitudinal muscle. Silk loops
were tied at both ends of the strips. The muscles were
suspended vertically in 5-ml organ chambers (Radnoti
Glass Technology Inc., Monrovia, CA) ﬁlled with
modiﬁed Krebs-Ringer bicarbonate solution main-
tained at 37.5 C and bubbled with 95% O2 and 5%
CO2 (Carbagas, Bern, Switzerland). The lower end
of the muscle strip was connected to a ﬁxed glass
hook in the chamber, and the upper end was attached
to a noncompliant force transducer (Radnoti Glass
Technology Inc.), thereby allowing measurement of
isometric force.
Experimental Design
After an equilibration periodof 80–90minutes with
change of the buffer solution every 20–25 minutes,
each strip was stretched incrementally at 10- to 15-
minute intervals to its optimal length (Lo). Lo is de-
ﬁned as the length beyond which further stretching
did not increase the amplitude of spontaneous con-
tractions. The entire experiment was then performed
at this Lo; strips without spontaneous activity were
not used (2% of all muscle strips).
After recording of baseline spontaneous activity,
one substance was administered per chamber in a
cumulative manner every 10 minutes. Norepineph-
rine (NE) was chosen as the nonselective adrenergic
agonist; phenylephrine and clonidine as α1- and α2-
selective agonists; and prenalterol, ritodrine, and
ZD7114, as β1-, β2-, and β3-selective agonists, respec-
tively. Drugs were added in cumulative doses (107 to
3 × 105 M) every 10 minutes. The highest dose used
was 3 × 105 M according to our previous work using
only NE.5,6 One chamber contained a control strip
to conﬁrm stable activity during the duration of the
experiment, and the ﬁnal chamber contained a spare
strip.
After the dose-response experiment, the chambers
were washed 4 times with modiﬁed Krebs-Ringer
buffer. When spontaneous contractions returned to
baseline activity, tetrodotoxin (TTX; 106 M) was
added to every chamber. TTX is thought to abolish
most all enteric neural input by blocking neuronal
sodium channels. After a 15- to 20-minute equilibra-
tion, the same dose-response experiment was re-
peated in each chamber with the same agonist.
At the conclusion of the experiment, the length of
each strip between the two ties of silk loops and wet
weight was measured.
Data Analysis
Total spontaneous contractile activity was quanti-
ﬁed as the integral of the generated force (g × time
as total area under the contractile curve) measured
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agonists were quantiﬁed by measuring the integral of
force for 5 minutes immediately after drug adminis-
tration. The integral of force was calculated by
computerized methodology using special software
(AcqKnowledge, Biopac Systems, Inc., Goleta, CA),
normalized per millimeter squared of cross-sectional
area (CSA) for each muscle strip.
The CSA was calculated using the following
equation:
CSA (mm2)  Tissue wet weight (mg)/Tissue
length (mm) × Tissue density (mg/mm3)
Tissue length and weight were measured at the end
of the experiment, and smooth muscle tissue density
was assumed to be 1.05 mg/mm.3,8
The dose-response curve for each agonist was ob-
tained by deﬁning spontaneous contractile activity as
100%. To quantify these dose-response curves, the
negative of the natural log (In) of the equipotent
concentration that caused a 50% response (EC50) wasestimated for each agonist based on the dose-response
curve. A greater EC50 represents a smaller concentra-
tion of an agonist needed to induce 50% inhibition
of spontaneous activity.
Values are presented as mean  SEM. Student’s
t tests with a Bonferroni correction were used to
compare the effects of each speciﬁc agonist with spon-
taneous activity at all doses and with the respective
effect of NE. The effect of TTX on spontaneous
activity, on EC50, and on each dose of the respective
agonist was evaluated in the same way.
Drugs
L-Phenylephrine hydrochloride, clonidine hydro-
chloride, ritodrine hydrochloride, and norepineph-
rine bitartarate salt were purchased from Sigma (St.
Louis, MO). Prenalterol and ZD7114 hydrochloride
were purchased from Astra Zeneca (So¨derta¨lje,
Sweden). TTX was purchased from Juro (Luzern,
Switzerland).Fig. 1. Effect of norepinephrine (A) and phenylephrine (α2) (B) on spontaneous activity. Cumulatively
administered molar doses of agents caused a dose-dependent decrease in contractile activity.
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Spontaneous Contractile Activity
Spontaneous phasic contractile activity was re-
corded shortly after suspending the muscle strips in
the organ chambers. After the addition of TTX (after
the ﬁrst adrenergic dose-response experiments, wash-
out, and restoration of spontaneous activity), contrac-
tile activity was reduced slightly from 77  8 to
73  8 (g/5 min/mm2; P  0.01).
Effect of Nonselective Adrenergic Stimulation
In all strips treated with NE, the amplitude and
the baseline tone were reduced in a dose-dependent
manner, whereas the frequency of contractions re-
mained unchanged. At the higher doses, an initial
increase in basal tone was observed (Fig. 1A). Inhibi-
tion of spontaneous contractile activity induced by the
highest dose of norepinephrine (3 × 105 M) was
65  6%.Blocking all neural activitywithin the bowel
wall with TTX (106 M) did not change the dose-
response to NE (Table 1) nor the effect of the highest
dose of NE on baseline tone (Table 2).
Effect of a-Agonists
Phenylephrine (α1-agonist) inhibited contractile
activity by reducing the amplitude but not the basal
tone in a dose-dependent fashion (Fig. 1B). However,
the EC50 was less than that for NE, and the inhibition
(at 3 × 105 M) was less compared with an equimolar
dose of norepinephrine (Table 1; Figs. 1, 2A). TTX
had no effect on α1-receptor–mediated inhibition in-
duced by phenylephrine. However, if only changes
in baseline tone were analyzed, TTX slightly in-
creased the change of baseline tone induced by the
highest dose of phenylephrine (3 × 105 M; 35  5%Table 2. Reduction of baseline tone induced by
adrenergic agonist without or with tetrodotoxin
(TTX; 106 M)
Response to 3 × 105 M dose*
Without TTX With TTX
Norepinephrine 75  9 80 6
Phenylephrine, α1 35  5 43 4†
Clonidine, α2 7  4 20 4
Prenalterol, β1 26  4 32 6
Ritodrine, β2 66  8 45 6†
ZD7114, β3 58  7 60 7
*Values represent percent (mean  SEM; n  8 rats) reduction of
baseline (one after the highest dose of agonist (3 × 105 M) compared
with baseline tone before dose-response experiment (100%).
†P  0.05 compared with without TTX.
versus 43  4%, P  0.05; Table 2). Clonidine
(α2-agonist) with and without TTX had no demon-
strable effect on contractile activity.
Effect of b-Agonists
Differing effects of the three β-adrenergic ago-
nists were noted. Prenalterol (β1-agonist) with or
without TTX had no effect. In contrast, ritodrine
(β2-agonist) and ZD7114 (β3-agonist) both induced
a marked, dose-dependent effect with inhibitions of
39  3% and 46  7% at 3 × 105 M doses, respec-
tively (Table 1, Figs. 2B, 3).TTXdidnot inﬂuence the
dose-response of ZD7114 (β3-agonist), but TTX
reduced the inhibitory effect of 3 × 105 M ritodrine
(β2-agonist) from 46  7% to 35 6% (P  0.05);
the EC50, however, did not change (Table 1). This
decrease in inhibition seems to be due primarily to
a lesser reduction in the basal tone (Fig. 4). Ritodrine
(3 × 105 M; β2-agonist) reduced basal tone byTable 1. Inhibitory effect of selective adrenergic agonists on rat ileal longitudinal muscle without
and with tetrodotoxin (TTX; 106 M)
Response to 3 × 105 M dose* EC50
Without TTX With TTX Without TTX With TTX
Norepinephrine 65 6† 70  5† 5 0.3 5.3  0.7
Phenylephrine, α1 31 5†‡ 30  6†‡ 1.5 0.7‡ 2.3  1.2‡
Clonidine, α2 5  3‡ 13  7‡ NA NA
Prenalterol, β1 9  4‡ 15  2†‡ NA NA
Ritodrine, β2 46 7†‡ 35  6†‡§ 3.5 0.4‡ 3.0  0.6‡
ZD7114, β3 39 3†‡ 42  4†‡ 4.4 0.6 4.4  0.4
EC50  calculated negative log of molar value resulting in 50% inhibition of spontaneous activity; NA  not applicable, because no inhibition
was seen.
*Values given as percent inhibition, mean  SEM; n  8 rats.
†P  0.005 compared with norepinephrine.
‡P  0.06 compared with spontaneous activity before adding respective drug.
§P  0.05 compared with same dose without TTX.
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prenalterol (PREN) (β1), ritodrine (RIT) (β2) and ZD7114 (ZD) (β3) compared with norepinephrine
(NE). Values given as mean  SEM; n  9 rats. *P  0.05 versus NE.
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caused a dose-dependent decrease in basal tone and thus in contractile activity.66  8%. In the presence of TTX, the reduction in
baseline tone was smaller (45  6%, P  0.05).
The EC50 for ZD7114 did not differ from the
EC50 of NE (4.4  0.6 versus 5.0  0.3), suggesting
a similar molar inhibitory effect by ZD7114. The
EC50 of ritodrine andNE (3.5  0.4 versus 5.0  0.3,
P  0.05) differed; the dose-response curve for rito-
drine was shifted to the right, compared with NE
(Fig. 2B).
DISCUSSION
Our study was designed to characterize the
involvement of speciﬁc adrenergic α1-, α2-, β1-, β2-,
or β3-receptor mechanisms in the inhibition of con-
tractile activity of longitudinal smooth muscle in the
rat ileum. These contractile responses are of particu-
lar interest, because modulation of gut motility via
adrenergic pathways may represent a novel therapeu-
tic target for motility disorders. This pharmacologic
approach would require identiﬁcation of speciﬁc re-
ceptor subtype mechanisms such that effects on intes-
tinal contractile function can be targeted, possibly
minimizing or even avoiding cardiovascular side
effects.Our main ﬁndings were that α2- and β1-receptor
mechanisms do not appear to be involved in the adren-
ergic modulation of gut contractile activity in the rat,
neither directly on the smooth muscle cells nor indi-
rectly via the enteric nervous system. In contrast, α1,β2, and β3 pathways reproduced, in part, the inhibition
induced by norepinephrine, a nonselective, global ad-
renergic agonist. Blocking enteric neural activity
within the muscle strip (with TTX 106 M) par-
tially reduced the response of β2-receptor and slightly
increased the response of α1-receptor stimulation,
suggesting involvement of enteric neural mechanisms.
The involvement of α1- but not α2-receptors in
the control of motor activity in the rat ileum is of
special interest, because in general not much is known
about the role of α-receptors in intestinal contract-
ility. A case report of a patient with pheochrom-
ocytoma in whom paralytic ileus was treated
successfully with the α-receptor antagonist phentol-
amine and later with prazosin (selective α1-receptor
agonist)9 suggests that α-mechanisms may be in-
volved in human small bowel contractile activity,
whereas in an in vitro study in human tissue, α2
pathways did not seem to play a role.10 Therefore,
it seems likely that in control of human small bowel
contractility, α-adrenergic inﬂuence is dependent on
α1-receptors. This would be in accordance with our
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caused a dose-dependent decrease in contractile activity. (B) In presence of tetrodotoxin, the dose-
dependent reduction in basal tone was smaller, thus reducing the overall inhibitory effect induced
by ritodrine.results in rat ileum where α1 mechanisms but not α2
pathways appear to inﬂuence contractile properties
in vitro. However, in the gut of other species, the
role of α-receptors is different: in guinea pig ileum,
both α1- and α2-receptors mediate inhibition,11 and
in canine and mouse ileum and in rat colon, only α2,
not α1, inhibitory mechanisms have been de-
scribed.12–14 In rabbit, α1 mechanisms can be part of
inhibitory pathways in other anatomic regions of the
gut such as jejunum15 and duodenum.16 Because of
marked species differences, broad generalizations be-
tween species must be made with caution.
Inhibitory mechanisms mediated by β2-adrenergic
receptors were identiﬁed in our study. This ﬁnding
is consistent with results in rabbit ileum,17 whereas
in canine ileum, β2 pathways had no inﬂuence on
contractile activity.12β3-Receptors have been of particular interest be-
cause they seem to be abundantly present in gastroin-
testinal tissue.18,19 Our results are in accordance with
the data of Brown and Summers,20 who showed that
β3 pathways play a major role in the inhibition of
rat ileum. In guinea pig ileum, contractile activity
is also inhibited by β3-receptor stimulation,21 whereas
canine ileum does not seem to be inﬂuenced by β3-
receptors.12
As discussed earlier, β2- and β3-receptor–speciﬁc
inhibition plays a role in inhibiting contractile activ-
ity, whereas β1-receptor mechanisms do not appear
to be involved in the inhibition of longitudinal muscle
of the rat ileum. Our latter ﬁnding contrasts with
data from Brown and Summers,20 who reported a
slight effect of β1-receptor mechanisms in rat ileum.
Differences in the muscle layers investigated and in
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stances that were used and conduction of the experi-
ment in precontracted muscle strips, may explain
some of these differences. We have shown previously
that different contractile responses in circular versus
longitudinal muscle layers are as important as are
differences between anatomic regions of jejunum
versus ileum.22,23 In an in vivo study in canine
ileum that supports our results, β1-receptors were
found to not be important.12
In our experiments, we tried to distinguish between
muscle-related mechanisms and pathways involving
the enteric nervous system, because under pathologic
conditions, adrenergic mechanisms might be com-
promised at either level of control.5,24,25 None of the
speciﬁc adrenergic α2-, β1-, or β3-receptor mecha-
nisms were TTX sensitive, and therefore the path-
ways seem to be independent of the enteric nervous
system. Interestingly, part of the β2 and α1 inhibition
in our experiments appears to be modulated by pre-
synaptic mechanisms. Blockade of neural β2 mecha-
nisms by TTX resulted in a lesser inhibition of
contractile activity. This neurally mediated effect ap-
pears to occur via a reduction in baseline tone rather
than a reduction in phasic activity. In contrast, the
α1-adrenergic effect appears to be related to a slight
increase in baseline tone. The physiologic relevance
of theseﬁndings as seen in our in vitromeasurement of
isometric contractions is not yet known. In other
study designs, the distinction between muscle or neu-
rally mediated inhibition was not made.17 However, it
is conceivable that part of the gastrointestinal motility
disorders in neurologic diseases such as diabetic neu-
ropathy or other postneurotomy syndromes (e.g.,
postvagotomy gastroparesis) are linked with an im-
paired modulation of contractile activity via β2 and
α1 mechanisms. Thus, further studies are required.
CONCLUSION
Because none of the speciﬁc pathways alone
reached the degree of inhibition achieved by NE,
we conclude that adrenergic inhibition in rat ileum
may be an additive effect of the three speciﬁc adrener-
gic mechanisms noted to inhibit contractile activity
(α1, β2, and β3). This concept of the involvement of
several receptors in inhibitory mechanisms is sup-
ported by previous results in rabbit ileum17 and by
studies in human colon byManara et al.26 Possibly, the
known plasticity of the gut may allow one receptor
to take over for another receptor under various
conditions. Hutchinson et al.27 showed that β1-adre-
noceptors may compensate for β3-adrenoceptors in
adrenoceptor-mediated relaxation of ileal musclefrom β3-adrenoceptor knock-out mice, and Susulic
et al.28 Suggest that “cross-talk” might exist between
β3-adrenoceptors and β1-adrenoceptor gene expression.
Our results, when compared with the literature,
underline the high degree of variability not only in
regional dependent differences (anatomic and muscle
layer) but also between species. It is of interest that
α1-receptormechanisms (but notα2 pathways) played
a role in our rat ileum study. The scarce data from
the literature suggest a similar constellation of con-
tractile α mechanisms in human small bowel. If this
similarity is conﬁrmed in the future, the rat ileum
might be attractive to further model α1 pathways in
pathologic states.
For β2- and β3-receptors, species differences are
evident as well, but we do not have comparable data
for human ileum. Species differences, especially for
β3 pathways, would be of interest, because these re-
ceptors are abundantly present not only in adipose
tissue but also in gastrointestinal tissue and there-
fore are of interest for the study of gastrointestinal
motility.29,30 To our knowledge the role of β3-recep-
tors in human contractility has not been carefully
investigated in vitro.
Because of the species differences of adrenoceptor
distribution and function, choosing the right animal
model is crucial. This has been noted for cardiovascu-
lar studies17 and will be the same for contractile stud-
ies of the gastrointestinal tract.
The authors thank Dr. M. G. Sarr for his valuable input to the
manuscript.
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